Home » ETF » PJP

PJP - Invesco Dynamic Pharmaceuticals ETF

Stock Price: $79.38 USD -0.54 (-0.68%)
Updated Apr 19, 2021 4:00 PM EDT - Market closed
Assets $367.63M
NAV $79.92
Expense Ratio 0.56%
PE Ratio 13.50
Beta (5Y) 0.86
Dividend (ttm) $0.56
Dividend Yield 0.70%
Ex-Dividend Date Mar 22, 2021
1-Year Return -
Trading Day April 19
Last Price $79.38
Previous Close $79.92
Change ($) -0.54
Change (%) -0.68%
Day's Open 79.98
Day's Range 79.17 - 79.98
Day's Volume 13,349
52-Week Range 59.27 - 81.86

Fund Description

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Pharmaceutical IntellidexSM Index. The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.

Asset Class
Equity
Sector
Biotech
Region
North America
Inception Date
Jun 23, 2005
Exchange
NYSEARCA
Ticker Symbol
PJP
Index Tracked
Dynamic Pharmaceutical Intellidex Index

Top 10 Holdings

51.40% of assets
NameSymbolWeight
PfizerPFE5.89%
AmgenAMGN5.81%
Gilead SciencesGILD5.50%
MerckMRK5.36%
Abbott LaboratoriesABT5.28%
AbbVieABBV5.19%
Johnson & JohnsonJNJ5.15%
Five Prime TherapeuticsFPRX4.86%
Eli LillyLLY4.80%
United TherapeuticsUTHR3.56%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Mar 22, 2021$0.153Mar 31, 2021
Dec 21, 2020$0.131Dec 31, 2020
Sep 21, 2020$0.117Sep 30, 2020
Jun 22, 2020$0.156Jun 30, 2020
Mar 23, 2020$0.136Mar 31, 2020
Dec 23, 2019$0.162Dec 31, 2019
Full Dividend History

News

Hide News
  • All
  • Videos
  • Conversation

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Other tickers mentioned: FTXH, IHE, PPH, XPH
2 months ago - Zacks Investment Research

Stocks came crashing on the first day of the New Year in apprehension of the outcome of the Georgia run-off elections.

Other tickers mentioned: ICLN, IFRA, IHF, ITOT, KRE, PKB, TAN
3 months ago - Zacks Investment Research

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

Other tickers mentioned: BBH, FBT, PBE, PPH
4 months ago - Zacks Investment Research

The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.

Other tickers mentioned: FTXH, PPH, PSCH, XHS, XPH
5 months ago - Zacks Investment Research

News that a Pfizer and BioNTech vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial has instilled more optimism in the markets.

Other tickers mentioned: IHF, JETS, KRE, ROOF, RYE
5 months ago - Zacks Investment Research

Though the counting process for the U.S. election outcome is still on, the prospect of a Joe Biden presidency marked by a divided Congress is rife.

Other tickers mentioned: CLOU, FDN, IHF, KBE, PPA, PSP, TAN ...
5 months ago - Zacks Investment Research

Easing worries regarding major policy changes are driving the relief rally in the healthcare and biotech spaces in the post-election period.

Other tickers mentioned: IBB, PPH, VHT, XBI, XLV
5 months ago - Zacks Investment Research

Chances of a dividend congress caused a superb rally in Wall Street the day after election.

Other tickers mentioned: CLOU, FDN, HCA, IHF, KBE, QQQ, XLK
5 months ago - Zacks Investment Research

The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.

Other tickers mentioned: FTXH, IHE, PPH, XPH
5 months ago - Zacks Investment Research

The coronavirus vaccine development effort has put the spotlight on the U.S. healthcare sector in recent months.

Other tickers mentioned: CNBS, GNOM, IHE, IHF, IHI, XHE
5 months ago - Zacks Investment Research

The best pharmaceutical ETFs for Q4 2020 are KURE, XPH, and PJP.

Other tickers mentioned: KURE, XPH
8 months ago - Investopedia

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

Other tickers mentioned: FTXH, IHE, PPH, XPH
8 months ago - Zacks Investment Research

Zacks recently issued quarterly rank updates for ETFs and these sector ETFs have been upgraded to Buy.

Other tickers mentioned: IYJ, IYZ, KBE, RTH, VFH, VOX, XPH
10 months ago - Zacks Investment Research

These sector ETFs emerged winners in the 11-year old bull market and may survive despite the coronavirus scare.

Other tickers mentioned: FBT, FDN, FXH, QTEC, VCR, XBI, XLY
1 year ago - Zacks Investment Research

Strong results led to solid trading in pharma ETFs over the past week.

Other tickers mentioned: FTXH, IHE, PPH, XPH
1 year ago - Zacks Investment Research

Pharma sector wins in October, making these ETFs and stocks winners.

Other tickers mentioned: DERM, GLYC, IRWD, PPH, RIGL, XPH
1 year ago - Zacks Investment Research

Robust results led to solid trading in pharma ETFs in a month.

Other tickers mentioned: FTXH, IHE, PPH, XPH
1 year ago - Zacks Investment Research

Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

Other tickers mentioned: BBH, IBB, IEIH, PBE
1 year ago - Zacks Investment Research

Despite robust results, pharma ETFs have been trending downward in a month.

Other tickers mentioned: FTXH, IHE, PPH, XPH
1 year ago - Zacks Investment Research

With the performance of the market this year, the bad ETFs that are slumping this year really stand out. Here are 7 funds to stay away from.

Other tickers mentioned: ECH, EWY, FCG, LIT, PXE, URA
1 year ago - InvestorPlace

Despite such robust results, pharma ETFs have been trending downward in a month.

Other tickers mentioned: FTXH, IHE, PPH, XPH
1 year ago - Zacks Investment Research